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Introduction
By Jeffrey V Lazarus.
In the last few years, as viral hepatitis has become a
more prominent issue on national and international
health agendas, talk of “learning from HIV” has become
quite common. It is understandable for researchers, pol-
icy-makers and activists to make this link, given the nota-
ble commonalities between HIV, hepatitis B and hepatitis
C. All are life-threatening blood-borne viruses that affect
hundreds of millions of people worldwide. All can remain
asymptomatic for many years, making it difficult to pro-
mote awareness of their danger. Ignorance about all of
the major forms of viral hepatitis, particularly B and C,
understandably reminds many people who are working
to confront this issue of the early years of the AIDS epi-
demic, when a combination of misinformation and
unwillingness to candidly address stigmatised behaviours
and social inequalities led to a widespread failure to for-
mulate a cohesive public health response.
Other parallels might be elucidated, and there is cer-
tainly good reason to think of the global HIV, hepatitis
B and hepatitis C epidemics as having similar trajectories
in some regards. Nonetheless, the differences between
HIV and viral hepatitis – in terms of how these varied
diseases manifest both biologically and socially – should
make us wary of oversimplifying the connection.
As discussions about hepatitis policies and strategies
gain momentum at the national and global level, it is
becoming increasingly important to articulate the
“lessons learned” from the HIV field. Pertinent issues
include disease prevention measures, testing and early
diagnosis, the scale-up of treatment, and barriers to ser-
vice uptake and retention in care. Key social and political
factors associated with viral hepatitis call to mind other
possible lessons relating to the value of civil society
engagement, leadership and governance issues, resource
mobilization including innovative financing, the causes
and consequences of stigma, and the role of social
science in addressing health threats.
This is clearly a rich and important realm of inquiry –
and it is time to move beyond the general calls to learn
from HIV and begin to systematically formulate specific
lessons. As a preliminary step, the following roundtable
presents the insights of a range of experts who were invited
to reflect on how experiences from the global response to
HIV might inform the global response to viral hepatitis.
Kicking off the discussion is Jens Lundgren, a renowned
HIV researcher, head of the new WHO Collaborating
Centre on HIV and Viral Hepatitis and co-founder of the
HIV in Europe Initiative. His perspective is much broader
than that of a medical doctor gazing at his own disease. In
the next two pieces, Jordi Casabona of the Epidemiological
Center for HIV/AIDS/STI of Catalonia and Lucas Wies-
sing of the European Monitoring Centre for Drugs and
Drug Addiction (and colleagues) consider surveillance and
monitoring issues. Sounding a cautionary note about the
“discourse of hope and expectation” associated with hepa-
titis C treatment, Magdalena Harris, a qualitative
researcher at the London School of Hygiene and Tropical
Medicine, critically reflects on treatment as prevention.
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The European Liver Patients Association raises a
number of key issues including how price reductions for
HIV treatment should inspire stakeholders to find ways
of making the newest hepatitis C medications more afford-
able. Leaders of the Correlation Network’s Hepatitis C
Initiative, which commissioned this supplement and which
is holding the first European Conference on Hepatitis and
Injecting Drug Use (October 2104), identify key actions to
address hepatitis based on lessons learned from HIV, with
a focus on people who inject drugs. Finally, in keeping
with the growing global emphasis on people-centred
health systems, Luís Mendão of Portugal, a leader of the
European AIDS Treatment Group, recounts what it is like
to live with both HIV and hepatitis.
Much to learn and adapt from over three decades
of HIV
By Jens Lundgren, Director of CHIP, Centre for Health
and Infectious Disease Research and WHO Collaborating
Centre on HIV and Viral Hepatitis.
HIV, hepatitis B and hepatitis C share many features
including common modes of transmission and the avail-
ability of effective treatment, albeit only curative for hepa-
titis C. As effective treatment was developed earlier for
HIV (1996) than for hepatitis B and hepatitis C (2004 and
2014, respectively), some important lessons on the public
health aspects of providing HIV therapy to those in need
may be informative to guide the public health response to
the two types of viral hepatitis.
A major dilemma in the HIV public health response has
been, and to some extent still is, the fact that no ideal
strategy has been developed for testing the population to
identify those infected. As a consequence, a large number
of HIV-positive people remain undiagnosed. As the infec-
tion remains asymptomatic early on, it is no surprise that
most undiagnosed people are in the early stages of infec-
tion, and only seek and receive a diagnosis when the infec-
tion has progressed and the patient develops AIDS or
other severe manifestations of the immunodeficiency
caused by the virus. These late presenters still constitute
some 50% of newly diagnosed HIV patients across Europe
[1]. Agreement on a definition of late presenters has been
an important tool incorporated into surveillance structures
to understand to what extent a large undiagnosed popula-
tion remains a problem. A definition of chronic viral hepa-
titis-infected persons who present late for care remains to
be established.
Along these lines, the estimation of the number of
undiagnosed people constitutes core knowledge that
should be helping to guide public health responses. Given
that those undiagnosed are not picked up by routine sur-
veillance, the critical missing link in the HIV response was
to use surveillance information as the basis for
mathematical models that can provide a reasonable esti-
mate of the number of infected and undiagnosed people
living with HIV in a given population. Multiple approaches
on how to resolve this are underway [2]. There is an
urgent need to initiate similar activities so that the number
of undiagnosed individuals with hepatitis B and hepatitis C
can be more reliably estimated.
Testing for HIV is a diagnostic technique similar to
other diagnostic techniques performed in people who
seek contact with the health system. The fact of the
matter is, however, that most HIV tests are done in spe-
cialised units, not by general practitioners. Research in
more recent years has demonstrated that many of the
undiagnosed people living with HIV come into contact
with the health system several times before they are
diagnosed with HIV. Each of these visits obviously con-
stitutes a missed opportunity to catch the person earlier
in the course of the infection. Mapping efforts are
underway to determine the conditions these people had
when approaching the health system [3]. The first set of
guidelines regarding which conditions should prompt
any health professional to offer an HIV test was released
in 2012 (http://www.hpa.org.uk/webc/HPAwebFile/HPA-
web_C/1317133743551), and the number of conditions
continues to expand (http://hiveurope.eu/Ongoing-Pro-
jects/HIDES/HIDES-2). This author’s personal view is
that the situation for undiagnosed hepatitis B and hepa-
titis C resembles that for HIV; future research should
document whether this view is correct. Additionally,
more proactive community-based testing is being imple-
mented for HIV, and the challenges associated with
linking those diagnosed with HIV to the health system
are being explored. The realisation that a comprehensive
testing approach utilising multiple and diverse
approaches tailored to the local situation should be the
standard for all three viral infections.
Health systems have adapted their approach to offering
HIV care. The patient community has been an active
partner in this adaptation process. Community clinics
and shared care models are being implemented. Linkage
to and retention in care are both critical indicators of
how effectively the health system is providing the care
required. The concept of understanding the “treatment
cascade” in the setting you are responsible for is becom-
ing a best-practice standard, with recognition that con-
certed actions should be implemented to understand and
resolve barriers to suboptimal performance. Mapping
exercises of the treatment cascade for hepatitis B and
hepatitis C will be critical to guide the public health
response and to ensure care for those in need of effective
therapy.
Much of the progress in refining the public health
response to HIV has been seen in the last decade. An
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important lesson from the process is that none of the key
stakeholders can do this by themselves. As such, civil
society, health professionals and policy-makers need to
collaborate and create a collegial atmosphere for the colla-
boration to be fruitful. Each of these constituencies brings
important knowledge and abilities to the process. This is
also true when considering the challenges associated with
hepatitis B and hepatitis C.
Above are some examples of progress made within the
HIV field that can be considered for modification and
adaption to guide a comprehensive and rational public
health response to viral hepatitis. That said, it is important
to also stress that whereas much progress in the public
health response to HIV has been achieved in the last dec-
ade, we have by no means a perfect system. Further refin-
ing the public health response to HIV will require
overcoming considerable challenges. But at least we are
now able to formulate a series of best-practice examples,
and in doing so, identify those that hold up well and those
where there is room for improvement.
Surveilling infectious diseases
By Jordi Casabona, Director of the Epidemiological
Center for HIV/AIDS/STI of Catalonia (CEEISCAT).
The aim of surveillance of infectious diseases is to
improve the prevention and control of these conditions
by public health authorities as well as to inform clinical
services to better deliver both prevention and treatment
programmes. Therefore, surveillance approaches and
strategies evolve in accordance with the knowledge we
have on the particular agent and the natural history of
the disease. They also evolve in response to the diagnos-
tic and therapeutic tools available. For instance, the
identification of HIV in 1983 and the development of
the first serological test in 1985 allowed for the design
and implementation of bio-behavioural studies among
specific sentinel populations. When in 1996 combination
antiretroviral therapy proved to be highly effective,
intense screening programmes to detect people living
with HIV were put in place; when later on it was
demonstrated that initiating treatment earlier could
improve clinical outcomes, early diagnosis strategies
were developed to decrease the number of HIV-infected
people who do not know they are infected.
All of this required surveillance strategies to evolve
over time to incorporate new methods and variables.
While HIV knowledge has been steadily accumulating
for the last 20 years, information about hepatitis C treat-
ment has increased significantly only during the last few
years. Information systems on HIV have been expanding
in scope and complexity over a long period of time, but
hepatitis C-related information systems are scarce. The
recent identification of new hepatitis C treatments that
can in most cases cure the patient forces public health
administrators to draw on the experience of monitoring
HIV and its diagnosis and treatment in order to rapidly
improve the coverage and quality of hepatitis-related
epidemiological, diagnostic and treatment efforts, for
instance incorporating hepatitis C data-gathering into all
formal HIV surveillance and observational studies.
Tackling hepatitis C among PWID in Europe: what
can we learn from HIV?
By Lucas Wiessing, Catharina Matheï, Peter Vicker-
man, Maria Prins, Mirjam Kretzschmar, Maria
Kantzanou, Isabelle Giraudon, Marica Ferri and
Paul Griffiths.
Chronic infection with the hepatitis C virus (HCV)
affects about 160 million people worldwide causing over
350,000 deaths per year [4-6]. In Europe, it is highly con-
centrated in people who inject drugs (PWID) due to trans-
mission related to the sharing of injecting equipment, and
this is now a key at-risk group [7-9].
Recent new treatments potentially could have a large
impact on HCV in PWID both in preventing liver dis-
ease and death, as well as further transmission, but their
high cost may hamper full implementation. Also, PWID
often have less access to healthcare due to stigma, dis-
crimination and repressive drug use policies [10]. While
coverage of traditional HCV treatments remains low in
PWID [11], despite recent reviews suggesting they
achieve similar cure rates, it remains to be seen if a
large scale-up with the new HCV treatments in PWID
is possible, similar to the universal HIV treatment access
policies adopted in the 1990s.
The EMCDDA monitors prevalence data of HIV, HBV
and HCV among PWID across 30 European countries,
enabling the tracking of trends in infection levels and the
identification of countries and regions at risk [7,12,13]. It
also monitors levels and trends in intervention coverage
(opioid substitution treatment and needle and syringe
programmes) [14] and population sizes of PWID. Addi-
tionally, behavioural indicators (e.g. needle sharing, HIV/
HCV testing) have recently been developed following a
second-generation HIV surveillance framework.
Modelling work initiated by and undertaken in colla-
boration with the EMCDDA has suggested that HCV pre-
valence may provide an important indicator of injecting
risks among PWID populations and that it may predict
the risk of HIV outbreaks in those populations [15,16].
This appears to have been confirmed in recent HIV out-
breaks in Europe, with increases in HCV prevalence pre-
ceding the increases in HIV transmission [12].
Based on methodology developed by the EMCDDA,
HCV prevalence data have thus been used to assess the
risks of HIV outbreaks across Europe, in combination
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with other risk indicators and indicators of intervention
coverage [17,18]. Several countries show increasing HCV
prevalence among PWID, suggesting an increased risk of
HIV transmission and potentially new HIV epidemics in
this population [12,13]. In addition, it has shown the
potential impact of antiretroviral therapy as prevention on
HIV incidence in populations of PWID.
Recently, the EMCDDA carried out a systematic review
of the availability of key data to guide the scaling up of
HCV treatment in PWID across Europe, as a complement
to the indicators routinely monitored (e.g. HIV and HCV
prevalence, PWID population size, intervention coverage)
[11]. The study indicated that data availability in several
areas of importance for HCV in PWID (e.g. incidence,
chronicity, diagnosis, treatment access and burden of dis-
ease) is limited, whereas the data that are available suggest
low rates of HCV diagnosis and HCV treatment entry
among PWID (higher data availability was found for geno-
types and HIV co-infection).
Based on the experience so far, three points can be
mentioned as conditions for effective policies regarding
HCV in PWID in Europe:
1. Given high HCV transmission coupled with low
levels of diagnosis and treatment among PWID, as well
as rapid developments in treatment effectiveness, the
case for full access to antiviral treatment for PWID is
becoming as pertinent as it has been for HIV since the
mid-1990s. This includes a need for renegotiation of
treatment prices at the EU level as current prices (up to
63 000 euros for one treatment) are prohibitive, espe-
cially where HIV is already incurring a large cost bur-
den. EMCDDA, in collaboration with key national,
European and international partners, is routinely report-
ing on trends in HCV and HIV epidemiology and pre-
vention coverage among PWID. However, HCV
treatment coverage monitoring is not in place and needs
to be implemented, while existing monitoring systems,
often still based on partial data, need to be strengthened
and consolidated.
2. The combination of observational (cohort and bio-
behavioural) and modelling studies has proven essential
for our understanding of epidemiology, intervention best
practice and policy options with regard to both HCV and
HIV in PWID [19, 20]. A stronger investment in multidis-
ciplinary studies using country-specific data with the aim
to support national policies is greatly needed.
3. PWID have many specific needs that extend beyond
HCV, including for example shared risk factors for HIV
and other infectious diseases, a high risk of death and
often serious social, somatic and psychiatric co-morbidity
and legal problems. These call for multifaceted and inte-
grated interventions, one of which is the treatment of
HCV infection. Sound public health policies need to
make full use of the existing expertise and specialised
data systems with regard to PWID in Europe in close col-
laboration and collegial exchange with the generalised
public health expertise and infrastructures at the national
and international levels.
A discourse of hope? Avoiding pitfalls with
‘treatment as prevention’ for hepatitis C
By Magdalena Harris, Lecturer, London School of
Hygiene and Tropical Medicine.
Current innovations in hepatitis C drug development are
reflected in a discourse of hope and expectation, with
references to “viral elimination” and “treatment as preven-
tion” increasingly noted in policy and academic literature
[21]. The concept of treatment as prevention (TasP), while
familiar to the HIV sector, is nascent in relation to hepati-
tis C. While this discourse reflects an increased sense of
treatment possibility, critical reflection on its implications
is warranted.
The linkage of hepatitis C treatment with prevention has
been occasioned by the advent of efficacious direct-acting
antivirals coupled with modelling work that illustrates the
impact of treating hepatitis C-infected people who inject
drugs (PWID) on the prevalent pool of the virus. This
population-based approach has implications for clinical
treatment decision-making, which is generally based on an
individualised assessment of potential treatment respon-
siveness and stage of disease progression. Treatment as a
prevention strategy requires the scale-up of treatment for
people who are currently injecting – an especially impor-
tant point in the context of the routine denial of treatment
for this priority population.
What, however, are the potential limitations of a TasP
framework? What are the conditions under which it
may be workable? Looking to the HIV field provides
some insights:
1. TasP must not undermine prevention as preven-
tion. Scholars such as Nguyen et al [22] have lamen-
ted the impact of TasP in re-medicalising the HIV
epidemic and subordinating primary prevention
funding to a treatment agenda. Harm reduction
initiatives for PWID such as needle and syringe pro-
grammes and opioid substitution therapy are already
fragile: politically unpopular (or prohibited) and
under-resourced. TasP is unsustainable without a
concomitant commitment to the up-scaling and
resourcing of harm reduction or “prevention as pre-
vention” initiatives.
2. Prevention initiatives must be community-owned
and community-led. In order for prevention initiatives
– including those involving hepatitis C treatment – to
be successful, they must be supported and endorsed by
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the affected community. TasP is premised on a popu-
lation level of analysis – the theoretical modelling
work on which it is based is divorced from the
grounded experience of people who navigate hepatitis
C and HIV risk in their daily lives. The acceptability
and uptake of interventions depend on engagement
with this experience and the meaningful involvement
of affected communities in their implementation. This
is particularly crucial in relation to PWID, for whom
criminalisation and systemic discrimination place fun-
damental barriers to service access.
3. TasP must not undermine social structural interven-
tions. For many PWID, hepatitis C is not a priority –
and may still not be even with the advent of more
efficacious treatments. Social structural barriers to
treatment access are reflected in peoples’ lives more
broadly – for many PWID, issues such as homelessness,
poverty and the threat of incarceration take precedence
over more long-term concerns such as hepatitis C. As
Nguyen et al comment, “treatment is not a substitute to
the removal of the vulnerabilities that place people at
risk of infection in the first place” [22]. In the absence
of resources for community empowerment and inter-
ventions tackling stigma and inequality, TasP is unsus-
tainable and potentially unethical.
4. Treatment is a human rights issue. A population-
based impetus to increase treatment access and
uptake among PWID can place an unwelcome onus
on already-marginalised individuals to undertake
treatment for which they may not be ready or will-
ing. In the absence of needed resources, TasP threa-
tens to locate responsibility for low treatment uptake
with the affected community rather than with the
social institutions and conditions generative of treat-
ment access obstacles. It is imperative that hepatitis
C treatment – currently unobtainable for the major-
ity of PWID – is made accessible to all. The ratio-
nale for this access must, however, be in relation to
the human rights of all to treatment access, rather
than in relation to a population-based imperative
aimed at disease control.
What difference does this emphasis make? Locating
hepatitis C treatment as a human right, rather than a
viral eradication issue, acknowledges the fundamental
rights and humanity of the most marginalised, including
the right of individuals to choose to access treatment –
or to decline. It is only on this basis that meaningful
and effective community engagement in hepatitis C
treatment delivery and advocacy can be mobilised. Such
engagement and advocacy have been transformational in
regard to HIV treatment access, but have been sorely
lacking thus far in the response to hepatitis C.
A perspective from the European Liver Patients
Association
By Margaret Walker and Lilyana Chavdarova of the
European Liver Patients Association.
In the years since its establishment in 2005, the
European Liver Patients Association (ELPA) has seen
many changes in the way in which liver disease, and
particularly viral hepatitis, is perceived. As a result we
acknowledge the importance of working in a more hol-
istic manner, ensuring that the wheel is not reinvented
over and over again. There is clearly no time to waste!
Ignoring the importance and value of experience in
other disease areas is both counterproductive and
limiting.
The HIV community has a vast amount of experience
which has been documented over the years and which is
extremely useful to those of us now working in the viral
hepatitis arena. A number of lessons can, and should, be
taken on board. For example, awareness-raising is one
area which warrants a greater focus. Policy-makers,
health professionals and the general public are only able
to react if they have all of the facts and information in
hand. Stigma is an avoidable aspect of viral hepatitis
which is strongly linked to lack of knowledge and under-
standing. The only way to combat it is through education
and by giving a face to the disease. In addition to World
Hepatitis Day reminding us to “think again,” we need to
emphasise to all interested stakeholders that hepatitis C
is the 8th biggest killer worldwide yet receives much less
attention than other diseases. We should also highlight
the fact that people from all walks of life can be, and are,
affected by viral hepatitis – the disease does not just
touch those who suffer from it but also their immediate
and extended families.
Pricing issues are extremely topical at the moment.
With new antiviral medications coming into the market,
the potential now exists to cure 90% of hepatitis C
cases, but pricing is a growing concern. Access to treat-
ment remains one of the key issues for patients, and
measures similar to those implemented to tackle the
HIV epidemic are needed. These measures could
include (but are not limited to) diversified licensing
options, large availability of generics and high-volume
procurement. In addition, it would be useful to look at
the option provided by pricing differentiation, since
experience has proven that the current external pricing
system needs to be modified to meet the needs of
European Union member states advancing at different
speeds.
Last but not least, increased efforts to identify hepa-
titis in high-risk groups, such as those seen for HIV,
are greatly needed, as is pinpointing and making use of
best or better practices. This is very much linked to
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affordable and readily available testing for those at risk.
Having the different stakeholders concerned working
together and using one voice is clearly key to tackling
hepatitis C, in particular given the limits placed on all
of us by limited resources and capacities.
Lessons learned from HIV, which can contribute
to the global response to hepatitis
By Eberhard Schatz, Katrin Schiffer, John Peter Kools
and Jason Farell of Correlation – European Network
Social Inclusion and Health.
The HIV/AIDS movement ensured a high level of
awareness, political commitment, programmes and
funding through the years, while at the same time the
hepatitis C epidemic among people who inject drugs
(PWID) has been neglected for more than 20 years.
When hepatitis C was addressed in the past, it was
solely represented as an HIV/AIDS co-infection, with
the specific challenges of hepatitis C ignored.
Tailored hepatitis C prevention, testing, treatment and
care interventions are needed. The world is clear about
this, as demonstrated by the new hepatitis resolution
passed by the World Health Assembly in May 2014.
The question now is when such interventions will be
implemented broadly in all European countries to the
same extent as HIV activities.
Advocates, community members and other stakeholders
in the area of hepatitis C should rely on lessons learned
from the HIV/AIDS epidemic, and could learn from meth-
ods and achievements such as taking a more proactive
policy approach both nationally and internationally.
In our opinion, some of the key actions suggested by
lessons learned from the three-plus decades of the HIV
epidemic are the following:
General
• Address the economic impact and public health
burden. By doing so, the development and implemen-
tation of tailored and effective prevention, testing,
treatment and care responses become a logical and
rational necessity.
• Create a critical mass of urgency and political will.
Hepatitis C among PWID is also an issue of stigma
and marginalization. These factors cannot only be
addressed by doctors and other health professionals.
• Engage different communities to reduce stigma
and provide additional support.
• Involve charismatic and popular “influencers” who
can create awareness among the general public.
• Through hepatitis C, give a ”face” and therefore a
voice to PWID.
• Empower PWID and involve them actively in all
advocacy and policy activities.
Political
• Link universal access to prevention, treatment and
health care with an overall human rights agenda.
• Build a case for affordable pricing of effective treat-
ment regimes.
• Advocate for effective prevention, testing, treat-
ment and care programmes at local, regional,
national and international levels.
• Ensure a strong commitment from international
health organisations including the World Health
Organization.
• Advocate for targeted hepatitis C strategies, interven-
tions and action plans, and insist that every country in
the world has a national strategy.
Prevention
• Scale-up comprehensive harm reduction services,
including blood-awareness campaigns to ensure
required protection.
• Develop and implement interventions to promote
safer “route of transmission” campaigns. Alternatives
to injecting are effective in the long term.
Treatment and care
• Establish treatment and care systems consisting of
multi-disciplinary teams and integrated services to
provide a holistic approach and to ensure that drug
users receive all needed support.
• Invest in community-based and other high-impact
and low-threshold interventions and care systems.
• Involve family and friends in the development and
implementation of family-focused care to support
drug users during the hepatitis C treatment phase
and to create support for professional services.
Testimony of an HIV/hepatitis C patient with AIDS
and advanced hepatitis C disease
By Luís Mendão, a former drug user and sexually non-
orthodox activist and advocate since 1982. Cofounder of
G.A.T. – Grupo Português de Activistas sobre Tratamen-
tos de VIH/SIDA – Pedro Santos and member of the
European AIDS Treatment Group.
Hepatitis C affects millions of people. The number of
deaths due to liver disease progression will grow if adequate
public health policies are not urgently implemented. I am
deeply convinced that the involvement of people using
drugs and living with hepatitis C in all levels of public policy
and programmes to control the epidemic is crucial, so here
goes:
I’m Luís Mendão, born in Portugal, 57 years old,
heavy nicotine smoker, free from sex and other drugs
for a while.
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In September 1996, I was taken to the hospital emer-
gency department where a young doctor on duty closed
the door and told me that my situation was very serious.
I had an infection. My lungs were affected, and I had a
severely compromised immune system.
Luís – I thought – you have been gladly promiscuous
with many people, male and female, some of them also
quite promiscuous, and the truth is that you almost always
used condoms, but not always.
Luís – I kept recalling – you experimented and
enjoyed drugs, some injected, a few times. Are you sure
you never shared equipment?
The fear that sex, which was a source of joy and wonder,
could have turned into a source of illness and death, was
unbearable. If I could share one recommendation it would
be related to this anxiety: opt-in for safer sex, and never
share injection materials.
We are not obligated to preach abstinence from sex or
drugs, but safe sex and not sharing needles are effective in
preventing both HIV and hepatitis C transmission. Also, if
you had previous risky behaviours, even if only once, get
tested for HIV and for hepatitis C. It’s the only way to
know if you live with it. You are not obliged to change
what you do, but do it more safely, and remember that
only by knowing your status can you treat the infections.
Treatment exists, and is more and more effective.
I was eventually transferred to the infectious disease
ward after confirmation of diagnosis. My laboratory
results from September and October 1996 indicated that
I had AIDS, a CD4 count of 2, a viral load of 890,000 and
terrible liver analysis scores. I figured I would have six to
12 months to live.
I sought information on the disease, to know what to
expect. I got a book, well written and clear, that described
its progression. My doctor asked me about my expecta-
tions. I told him I wanted the rest of the autumn and win-
ter to solve my life, and the spring to say goodbye to the
ones I loved. If he could offer me the summer as a bonus,
my happiness would be complete. I think he noted it – he
notes everything in his beautiful handwriting. He asked
me if I felt able to comply with a rigorous and complex
treatment. I said yes. I enjoyed myself a lot and organized
my days under this health totalitarianism.
The time I had left would be to live, have a loving life
and laugh. I decided to tell my friends and lovers (and to
get them to test as well), and the majority of my family,
but not my father and mother to spare them the suffering.
It was difficult waiting for the results of the tests, but one
by one my partners’ results came, all negative for HIV.
Two months later I had a CD4 count of 211 and an
undetectable viral load.
HIV treatment was already effective in 1996 (though
there were difficult side-effects, adverse events and a
heavy pill burden). The lucky ones had access. Portugal
at the time was on the right side of the planet, triple-
combination therapy was accessible, and I was saved.
The summer of 1997 was ending, I had said goodbye to
everyone, and death was not coming. I walked the “San-
tiago Way,” 45 days on foot with a 10 kg backpack, got
married, and as money began to fail I went back to work
in 1998. I joined the European AIDS Treatment Group
in 1999 and founded the Portuguese group GAT –
Grupo Português de Ativistas sobre Tratamentos de
VIH/SIDA – in 2001.
In 2003, my liver fibrosis was worsening and hepatitis
C progression became my major health issue, not AIDS.
I tried pegylated interferon and ribavirin – two months of
horror and torture, with no results. I was a null responder
- intolerant to interferon. I was hospitalized for two
months after stopping the treatment. I am a male over the
age of 45 with a high body mass index, with diabetes, fatty
liver, genotype 1a, a high viral load and later I found out
I’m non-CC – the genotype more likely to be cured by
HCV treatment. At the time, all were predictors of poor
treatment outcomes. But treatment in hepatitis C is chan-
ging, and the perspectives are good.
There is much we can learn from our past efforts in the
field of HIV. It is imperative, first of all, that responding
to the hepatitis C epidemic is part of the public agenda,
that both policymakers and communities are aware that
the problem exists, and that they understand what can be
done to prevent and treat it. A common strategy is
essential.
We need to provide treatment to all who require it.
This includes active drug users, but also so many more
people. Treatment is increasingly effective, but prices
are sky-high and issues of affordability rampant.
Integrated care systems to increase adherence and reten-
tion in treatment are very important, especially for people
with co-morbidities, as well as people in vulnerable social
or economic situations. There is a lot more to treatment
than just giving people pills.
Promoting access to clinical trials with new treatments
for people who lack viable treatment options should also
be considered whenever possible. Unlike other kinds of
viral hepatitis, there is no vaccine for hepatitis C, mak-
ing prevention efforts critical, including the provision of
safe injection equipment, opioid substitution therapy
and safe consumption rooms (for the most affected
group). Information on how to avoid transmission and
barrier-free HCV counselling, testing and linkage ser-
vices are also essential to stop the growth of the
epidemic.
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